Loading...
XASX
RGT
Market cap11mUSD
Apr 29, Last price  
0.42AUD
Name

MGC Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XASX:RGT chart
P/E
—
P/S
5.37
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
62.74%
Revenues
3m
-27.10%
02,627,9461,905,6622,110,860351,663000002,197120,242296,811656,2372,034,6492,962,8974,646,9883,387,567
Net income
-21m
L+20.17%
0-81,771-1,877,328-1,945,590-2,630,6591,935,168-290,880-766,897-5,337,815-3,797,791-6,157,144-8,144,361-8,246,340-1,903,672-20,022,987-13,504,469-17,328,780-20,823,584
CFO
-12m
L-28.76%
0-1,626,583-460,263-416,042-1,042,541-338,824-379,448-536,078-472,738-617,707-3,220,501-4,655,863-5,886,790-6,354,210-10,140,478-12,433,708-16,824,483-11,985,175

Profile

MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in Australia, Israel, and Slovenia. The company's principal product candidates include CimetrA, which is in phase III clinical trial for early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for symptomatic relief of Dementia. It has research and development agreement with Royal Melbourne Institute of Technology and the University of Notre Dame; and collaboration agreement with the Slovenian National Institute of Biology and Neurosurgery Department at the University Medical Centre. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.
URL
https://mgcpharma.com.au/
IPO date
Dec 21, 2006
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
3,388
-27.10%
4,647
56.84%
Cost of revenue
19,469
12,246
Unusual Expense (Income)
NOPBT
(16,081)
(7,599)
NOPBT Margin
Operating Taxes
190
Tax Rate
NOPAT
(16,081)
(7,789)
Net income
(20,824)
20.17%
(17,329)
28.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,451
9,998
BB yield
-16,633.73%
-24.35%
Debt
Debt current
9,370
151
Long-term debt
769
4,438
Deferred revenue
4,278
2,394
Other long-term liabilities
21
1,134
Net debt
9,899
2,646
Cash flow
Cash from operating activities
(11,985)
(16,824)
CAPEX
(190)
(4,018)
Cash from investing activities
606
(2,443)
Cash from financing activities
9,732
9,735
FCF
(13,499)
(6,434)
Balance
Cash
240
1,787
Long term investments
156
Excess cash
70
1,711
Stockholders' equity
(8,032)
11,056
Invested Capital
14,054
9,291
ROIC
ROCE
EV
Common stock shares outstanding
2,947
2,566,211
Price
0.01
-68.75%
0.02
-56.76%
Market cap
15
-99.96%
41,059
-41.78%
EV
9,285
43,145
EBITDA
(15,329)
(7,095)
EV/EBITDA
Interest
257
190
Interest/NOPBT